Skip to main content
SpringerLink
Log in

Fluoride therapy in postmenopausal osteopenic women: Effect on vertebral and femoral bone density and prediction of bone response

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Fifty-two postmenopausal women (mean age 60±5 years) with low BMD (<-2SD of young adult values) but who had not experienced previous crush fracture were treated with 50 mg of sodium fluoride (NaF), 1 g of calcium and 400 IU of vitamin D2 per day for 2 years. Repeated vertebral and femoral BMD measurements were made and compared with those of a control group consisting of 16 untreated women. Serum alkaline phosphatase and osteocalcin, blood and urinary fluoride levels were measured regularly to determine their predictive value on bone response. 18 of 52 (35%) of the treated patients experienced side effects (29% gastric, 4% lower extremity pain syndrome) but only in 6 cases (12%) was it necessary to discontinue treatment. In neither of the two groups was any fracture recorded (vertebral or otherwise). Among the 43 women who were treated for at least 2 years, 21 (49%) were considered to have responded (i.e., with an increase of vertebral BMD>0.043 g/cm2). There was a mean linear increase in BMD in this group of 0.0041 g/cm2 per month (i.e., 5.5% per year). On the other hand in the non-responder group and in the control group, vertebral BMD either remained stable or decreased. However no difference was detected between the two groups (treated and controls) at the femoral site after 2 years; both groups showed a significant decrease in BMD. The responders had a lower initial osteocalcin level and treatment led to a relatively greater increase in osteocalcin. Moreover basal and post-treatment levels of alkaline phosphatase and blood and urinary fluoride did not differ significantly between the two groups. An increase in serum osteocalcin of more than 50% had the best predictive value for bone response. However, this increase did not allow bone response to be predicted any earlier than direct bone measurement; the majority of responses being identified after 12–18 months of therapy. This study shows the ability of NaF to increase vertebral BMD without altering femoral density in women with low vertebral BMD but no fracture. However it is impossible to predict to what extent this increase in BMD will modify the ultimate risk of fractures.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eriksen EF, Hodgson SF, Riggs BL. Treatment of osteoporosis with sodium fluoride. In: RIGGS BL, MELTON III LJ, eds. Osteoporosis etiology, diagnosis and management. New York: Raven Press, 1988;415–32.

    Google Scholar 

  2. Heaney RP, Baylink DJ, Johnston CC. Fluoride therapy of the vertebral crush fracture syndrome. A status report. Ann Intern Med, 1989; 8:678–80.

    Google Scholar 

  3. Riggs BL, Hodgson SF, O'Fallon WM et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med 1990; 322:802–9.

    PubMed  Google Scholar 

  4. Kleerekoper M, Peterson E, Phillips E, Nelson D, Tilley B, Parfitt AM. Continuous sodium fluoride therapy does not reduce vertebral fracture rate in postmenopausal osteoporosis. J Bone Miner Res 4(Suppl.1), 1989;376, (abstract).

    Google Scholar 

  5. Meunier PJ, Mamelle N, Delmas PD et al. Benefit-risk ratio of fluoride therapy in vertebral osteoporosis: comparison of sodium fluoride to monofluorophosphate. In: DeLuca HF and Mazess RB eds. Osteoporosis: physiological basis, assessment, and treatment. Amsterdam: Elsevier, 1990;pp181–6.

    Google Scholar 

  6. Hui SL, Charles W, Slemenda W, Johnston C. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989; 111:355–61.

    PubMed  Google Scholar 

  7. Ribot C, Tremollières F, Pouilles JM, Louvet JP, Guiraud R. Influence of the menopause and aging on spinal bone density in French women. Bone Miner 1988; 5:89–97.

    PubMed  Google Scholar 

  8. Pouilles JM, Tremollières F, Louvet JP, Fournie B, Morlock G, Ribot C. Sensitivity of dual-photon absorptiometry in spinal osteoporosis. Calcif Tissue Int 1988; 43:329–334.

    PubMed  Google Scholar 

  9. Genant HK, Block JE, Steiger P, Glueer CC, Ettinger B, Harris ST. Appropriate use of bone densitometry. Radiology 1989; 170:817–22.

    PubMed  Google Scholar 

  10. Pak CYC, Sakhaee K, Zerwekh JE, Parcel C, Peterson R, Johnson K. Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures. J Clin Endocrinol Metab 1989; 68:150–9.

    PubMed  Google Scholar 

  11. Hansson T, Roos B. The effect of fluoride and calcium on spinal bone mineral content: a controlled, prospective (3 years') study. Calcif Tissue Int 1987; 40:315–17.

    PubMed  Google Scholar 

  12. Raymakers JA, Van Dijkel CF, Hoekstra A, Duursma SA. Monitoring fluoride therapy in osteoporosis by dual photon absorptiometry. Bone 1987; 8:143–8.

    PubMed  Google Scholar 

  13. Hodsman AB, Drost DJ. The response of vertebral bone mineral density during the treatment of osteoporosis with sodium fluoride. J Clin Endocrinol Metab 1989; 69:932–38.

    PubMed  Google Scholar 

  14. Briançon D, Meunier PJ. Treatment of osteoporosis with fluoride, calcium and vitamin D. Orthop Clin North Am 1981; 12:629–6.

    PubMed  Google Scholar 

  15. Duursma SA, Glerum JH, Van Dijkl A et al. Responders and non-responders after fluoride therapy in osteoporosis. Bone 1987; 8:131–6.

    PubMed  Google Scholar 

  16. Riggs BL, Seeman E, Hodgson SF, Taves DR, O'Fallon WM. Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis: comparison with conventional therapy. N Engl J Med 1982; 306:446–50.

    PubMed  Google Scholar 

  17. Mamelle N, Meunier PJ, Dusan R et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; ii:361–5.

    Google Scholar 

  18. Buckle RM. 3 years' study of sodium fluoride treatment on vertebral fracture incidence in osteoporosis. J Bone Miner Res 1989; 4(Suppl.1):187 (abstract).

    Google Scholar 

  19. Harrison JE, Bayley TA, Fosse RG et al. The relationship between fluoride effects on bone histology and on bone mass in patients with postmenopausal osteoporosis. Bone Miner 1986; 1:321–33.

    PubMed  Google Scholar 

  20. Budden FH, Bayley TA, Harrison JE et al. The effect of fluoride on bone histology in postmenopausal osteoporosis depends on adequate fluoride absorption and retention. J Bone Miner Res 1988; 3:127–32.

    PubMed  Google Scholar 

  21. Meunier PJ, Femenias M, Duboeuf F, Chapuy MC, Delmas PD. Increased vertebral bone density in heavy drinkers of mineral water rich in fluoride. Lancet 1989 i:152.

    Google Scholar 

  22. Farley SMG, Wergedal JE, Smith LC, Lundy MW, Farley JR, Baylink DJ. Fluoride therapy for osteoporosis: characterization of the skeletal response by serial measurements of serum alkaline phosphatase activity. Metabolism 1987; 3:211–18.

    Google Scholar 

  23. Gutteridge DH, Price RI, Nicholson GC et al. Fluoride in osteoporotic vertebral fractures - trabecular increase, vertebral protection, femoral fractures. In Christiansen C, Arnaud CD, Nordin BEC, Parfitt AM, Peck WA, Riggs BL eds. Osteoporosis Aalborg, Glostrup. Denmark: pp 705–7.

  24. Inkovara J, Heikinheimo R, Jarvinen K, Kasurinen U, Hanhijarvi H, Iisalo E. Prophylactic fluoride treatment and aged bones. Br Med J 1975; iii:73–4.

    Google Scholar 

  25. Hedlund LR, Gallagher JC. Increased incidence of hip fracture in osteoporotic women treated with sodium fluoride. J Bone Miner Res 1989; 4:223–5.

    PubMed  Google Scholar 

  26. Riggs BL, Baylink DJ, Kleerekoper M, Lane JM, Melton III LJ, Meunier PJ. Incidence of hip fractures in osteoporotic women treated with sodium fluoride. J. Bone Miner Res 1987; 2:123–6

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service d'Endocrinologie, U.F. Maladies Osseuses et Métaboliques, Toulouse, France

    J. M. Pouilles, F. Tremollieres, J. P. Louvet &  C. Ribot

  2. Laboratoire de Biochimie, Hôpital Purpan, Toulouse, France

    E. Causse

Authors
  1. J. M. Pouilles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Tremollieres
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Causse
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. P. Louvet
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Ribot
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pouilles, J.M., Tremollieres, F., Causse, E. et al. Fluoride therapy in postmenopausal osteopenic women: Effect on vertebral and femoral bone density and prediction of bone response. Osteoporosis Int 1, 103–109 (1991). https://doi.org/10.1007/BF01880451

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01880451

Keywords

Search

Navigation